SI3551209T1 - Inzulin-FC fuzije in postopki uporabe - Google Patents

Inzulin-FC fuzije in postopki uporabe

Info

Publication number
SI3551209T1
SI3551209T1 SI201730909T SI201730909T SI3551209T1 SI 3551209 T1 SI3551209 T1 SI 3551209T1 SI 201730909 T SI201730909 T SI 201730909T SI 201730909 T SI201730909 T SI 201730909T SI 3551209 T1 SI3551209 T1 SI 3551209T1
Authority
SI
Slovenia
Prior art keywords
fusions
insulin
methods
Prior art date
Application number
SI201730909T
Other languages
English (en)
Inventor
Thomas M Lancaster
Todd C Zion
Thillainayagam Sathiyaseelan
Sylaja Murikipudi
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Publication of SI3551209T1 publication Critical patent/SI3551209T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201730909T 2016-12-09 2017-12-08 Inzulin-FC fuzije in postopki uporabe SI3551209T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662432268P 2016-12-09 2016-12-09
US201762514460P 2017-06-02 2017-06-02
US201762514449P 2017-06-02 2017-06-02
US201762514427P 2017-06-02 2017-06-02
EP17878116.7A EP3551209B1 (en) 2016-12-09 2017-12-08 Insulin-fc fusions and methods of use
PCT/US2017/065456 WO2018107117A1 (en) 2016-12-09 2017-12-08 Insulin-fc fusions and methods of use

Publications (1)

Publication Number Publication Date
SI3551209T1 true SI3551209T1 (sl) 2021-10-29

Family

ID=62491387

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730909T SI3551209T1 (sl) 2016-12-09 2017-12-08 Inzulin-FC fuzije in postopki uporabe

Country Status (13)

Country Link
US (2) US11359001B2 (sl)
EP (2) EP3551209B1 (sl)
JP (2) JP7170332B2 (sl)
CN (1) CN110612112B (sl)
AU (2) AU2017371217B2 (sl)
BR (1) BR112019011860A2 (sl)
CA (1) CA3046337C (sl)
DK (1) DK3551209T3 (sl)
HR (1) HRP20211334T1 (sl)
HU (1) HUE055417T2 (sl)
LT (1) LT3551209T (sl)
SI (1) SI3551209T1 (sl)
WO (1) WO2018107117A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3551209T3 (da) 2016-12-09 2021-08-23 Akston Biosciences Corp Insulin-fc-fusioner og fremgangsmåder til anvendelse
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
LT3892628T (lt) 2018-06-29 2022-12-12 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
TW202039438A (zh) * 2018-12-11 2020-11-01 法商賽諾菲公司 胰島素接合物
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11352407B2 (en) 2019-12-19 2022-06-07 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP4248983A3 (en) 2020-04-10 2024-01-24 Akston Biosciences Corporation Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP4230216A1 (en) * 2020-07-24 2023-08-23 Jiangsu Gensciences Inc. Insulin-fc fusion protein and application thereof
WO2023004406A2 (en) * 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH07116160B2 (ja) 1987-08-10 1995-12-13 浜理薬品工業株式会社 結晶性ｌ−カルノシン亜鉛錯体およびその製造法
DE59010933D1 (de) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US20030040601A1 (en) * 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
WO2010117760A2 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
EP2598170A4 (en) * 2010-07-28 2016-07-06 Smartcells Inc MEDICAMENT-LIGAND CONJUGATES, THEIR SYNTHESIS AND CORRESPONDING INTERMEDIATES
AU2011282988A1 (en) * 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
BR112013032265A2 (pt) * 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
ES2749349T3 (es) 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
WO2013074598A1 (en) 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
PE20151409A1 (es) 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso
WO2016044676A2 (en) 2014-09-18 2016-03-24 AskGene Pharma, Inc. Novel feline erythropoietin receptor agonists
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
JP2018504911A (ja) 2015-01-29 2018-02-22 ネックスヴェット オーストラリア プロプライエタリー リミテッド 治療及び診断剤
US10894089B2 (en) 2015-02-17 2021-01-19 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue conjugate
ES2754432T3 (es) 2015-05-04 2020-04-17 Apogenix Ag Proteínas agonistas de receptor CD40 de cadena sencilla
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3757119A1 (en) 2015-11-16 2020-12-30 Ubiprotein, Corp. A method for extending half-life of a protein
WO2018009921A1 (en) 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion protein comprising leptin and methods for producing and using the same
TWI774694B (zh) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
DK3551209T3 (da) 2016-12-09 2021-08-23 Akston Biosciences Corp Insulin-fc-fusioner og fremgangsmåder til anvendelse
TW201835099A (zh) 2017-03-07 2018-10-01 美國凱斯西方瑞瑟夫大學 藉由第四雙硫鍵穩定之單鏈胰島素類似物
MX2020001707A (es) 2017-08-15 2020-03-20 Kindred Biosciences Inc Variantes igg fc para uso veterinario.
CN112423741A (zh) 2018-04-16 2021-02-26 犹他大学研究基金会 葡萄糖反应性胰岛素
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
LT3892628T (lt) 2018-06-29 2022-12-12 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
WO2020069011A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
US11649269B2 (en) 2018-10-05 2023-05-16 Novo Nordisk A/S Bifunctional compounds comprising insulin peptides and EGF(A) peptides
CN113330025A (zh) 2018-11-19 2021-08-31 卡斯西部储备大学 具有聚丙氨酸c结构域子区段的单链胰岛素类似物
AU2020279968A1 (en) 2019-05-17 2021-12-16 Case Western Reserve University Variant single-chain insulin analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
JP2022542301A (ja) 2019-07-31 2022-09-30 イーライ リリー アンド カンパニー リラキシン類似体およびその使用方法

Also Published As

Publication number Publication date
US11359001B2 (en) 2022-06-14
HRP20211334T1 (hr) 2021-11-26
CN110612112A (zh) 2019-12-24
AU2017371217B2 (en) 2020-03-19
AU2017371217A1 (en) 2019-07-25
US20200131243A1 (en) 2020-04-30
JP7170332B2 (ja) 2022-11-14
CN110612112B (zh) 2024-03-29
BR112019011860A2 (pt) 2019-11-12
JP2020503889A (ja) 2020-02-06
US20190315828A1 (en) 2019-10-17
JP2023017806A (ja) 2023-02-07
AU2020227002A1 (en) 2020-09-17
DK3551209T3 (da) 2021-08-23
CA3046337A1 (en) 2018-06-14
CA3046337C (en) 2021-06-01
US10597435B2 (en) 2020-03-24
HUE055417T2 (hu) 2021-11-29
EP3939605A1 (en) 2022-01-19
EP3551209A1 (en) 2019-10-16
AU2020227002B2 (en) 2024-02-01
WO2018107117A1 (en) 2018-06-14
LT3551209T (lt) 2021-09-10
EP3551209A4 (en) 2020-06-03
EP3551209B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1243102A1 (zh) 抗cd79b抗體和使用方法
IL250415B (en) Antibodies against pd-l and methods of using them
SI3551209T1 (sl) Inzulin-FC fuzije in postopki uporabe
HRP20181359T1 (hr) Anti-jagged1 protutijela i postupci uporabe
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
HRP20240603T1 (hr) Optimizirane fuzije binukleaze i postupci njihove upotrebe
GB201814832D0 (en) Shoulder braces and methods of use
HK1258850A1 (zh) 抗tpbg抗體及使用方法
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
GB201416797D0 (en) Contianer and method of use thereof